Timothys Ernst News Today

Platinum Investment Management Ltd. lessened its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 52.9% during the second quarter, Holdings Channel reports. The firm owned 8,636 shares of the medical research company’s stock after selling 9,706 shares during the quarter. Platinum Investment Management Ltd.’s holdings in Bio-Rad Laboratories were worth $3,274,000 […]

Thompson Siegel & Walmsley LLC boosted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 44.8% during the second quarter, Holdings Channel.com reports. The firm owned 294,164 shares of the medical research company’s stock after buying an additional 91,013 shares during the quarter. Bio-Rad Laboratories makes up approximately 1.8% of Thompson […]

Envestnet Asset Management Inc. lifted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 5.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 114,996 shares of the medical research company’s stock after purchasing an additional 5,761 shares during […]

Impax Asset Management Group plc boosted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 74.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,879 shares of the medical research company’s stock after acquiring […]

StockNews.com downgraded shares of Bio-Rad Laboratories (NYSE:BIO – Free Report) from a buy rating to a hold rating in a research report sent to investors on Monday morning. A number of other research firms also recently weighed in on BIO. Royal Bank of Canada lifted their price target on Bio-Rad Laboratories from $522.00 to $524.00 […]

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday. Several other analysts have also issued reports on BIO. Wells Fargo & Company cut their price objective on Bio-Rad Laboratories from $550.00 […]

Rowland & Co. Investment Counsel ADV lessened its position in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 16.1% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 1,227 shares of the medical research company’s stock after selling 235 shares during the quarter. Rowland & Co. Investment Counsel ADV’s holdings in Bio-Rad Laboratories […]

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) announced its quarterly earnings results on Thursday. The medical research company reported $2.33 EPS for the quarter, missing the consensus estimate of $2.87 by ($0.54), Briefing.com reports. Bio-Rad Laboratories had a negative net margin of 5.86% and a positive return on equity of 3.82%. The firm had revenue […]

Tobam acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 150 shares of the medical research company’s stock, valued at approximately $57,000. A number of other institutional investors also […]

Tobam purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 150 shares of the medical research company’s stock, valued at approximately $57,000. Other large investors have also modified their holdings of the company. Desjardins Global Asset Management Inc. bought a new stake in […]